ClinicalTrials.gg
RecruitingNCT07126509Updated Feb 17, 2026

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

An interventional study of Partial Pleurectomy in Mesothelioma, Mesothelioma; Lung and Mesotheliomas Pleural, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Primary conditionMesothelioma, MalignantRegistry: MesotheliomaReclassifiedWhy we changed it
Registry
Mesothelioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Mesothelioma, Malignant
Why
  1. The study's listed conditions name Mesothelioma, Malignant, a narrower term within Mesothelioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Chicago · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Mesothelioma, Malignant with a site in United States — 21 open to participants now, 38 under way, 1 of them phase 3. Mesothelioma, Malignant · United States.

Planned enrollment
75th of 145
30 · median 33
Started
2025
with 2 others
No phase
6 of 165
2 open now
Primary completion
2028-12
later than 28 of 36 live
Registered
162nd of 165
by date
Lead sponsor
5 of 165
University of Chicago

Among the 165 studies in Mesothelioma, Malignant with a site in United States, this one is the 75th largest by planned enrollment of the 145 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 with no phase, reaches primary completion later than 28 of the 36 other live ones, and was the 162nd registered.

Mesothelioma, Malignant

340 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

Browse Mesothelioma, Malignant studies →

Open to participants now

21 of the 165 studies in Mesothelioma, Malignant with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Mesothelioma, Malignant with a site in United States, or all of them as a file.
02

Study summary

Purpose of the study: The main purpose of this research study is to see if a surgery procedure (limited partial pleurectomy and decortication) helps symptoms in people who have cancer that is unresectable that might not be able to be removed completely. This is called unresectable cancer. This study will also help the research team learn more about the types of symptoms and quality of life for people who have undergone this surgery, the number of complications following , and the time from surgery to starting other therapy. Th e study team also wants to see see the overall survival of people who have had this procedure as part of their care.

What will be done as part of research on this study:

  • Surgery (Partial Pleurectomy - surgery to remove lining of lungs)
  • The research team will also ask study participants questions about their symptoms through questionnaires at certain times after surgery.

How long this study will last:

Participation in this research (pre-surgery, surgery and follow-up) will last for about 2 years.

Confidentiality: All personal information will be kept confidential, and data will be used only for research purposes.

Contact Information: For more information about this study, please contact PhaseIICRA@medicine.bsd.uchicago.edu

03

Conditions studied

  • Mesothelioma
  • Mesothelioma; Lung
  • Mesotheliomas Pleural
  • Mesothelioma Malignant Advanced
  • Mesothelioma, Malignant

Browse trials for

Keywords

  • PLEURECTOMY
04

In context

Mesothelioma, Malignant Reclassified

340 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

This study's planned enrollment of 30 is below the median of 39 across 272 interventional studies indexed under Mesothelioma, Malignant.

Browse Mesothelioma, Malignant studies →

Lead sponsor

University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.

Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.

Compared within Mesothelioma, Malignant, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mesothelioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed epithelioid subtype pleural mesothelioma, as determined by surgical (i.e. VATS) .
  • Disease confined to the unilateral hemithorax.
  • Disease that is classified as unresectable or borderline resectable:
  • Unresectable disease is defined by cross sectional imaging (CT or MRI) demonstrating invasion of unresectable mediastinal structures (heart, great vessels, esophagus) or spine, unresectable invasion of the chest wall (multifocal chest wall invasion or apical chest wall invasion), or disease outside intended resection field.
  • Borderline resectable disease is defined by cross sectional imaging (CT or MRI) demonstrating extensive pulmonary parenchymal invasion (anticipated need for anatomic resection or complex wedge resection to clear disease) or extensive/bulky disease of (1) the diaphragm or sulci (anticipated need for diaphragm resection and reconstruction to clear disease), or (2) the chest wall (anticipated need for chest wall resection and reconstruction to clear disease). Disease with pathologically proven hilar or mediastinal lymph node involvement.
  • Successful completion of at least 6 weeks of systemic induction therapy (regimen according to treating physician choice, including the below) with no unresolved adverse event that would preclude surgery:
  • Platinum agent, pemetrexed, +/- bevacizumab
  • Platinum agent, pemetrexed, pembrolizumab
  • Ipilimumab/nivolumab
  • Age ≥18 years.
  • performance status ≤1.
  • Patients must have adequate organ and marrow function as defined below:

    • leukocytes ≥3,000/mcL
    • ≥1,500/mcL
    • ≥100,000/mcL
    • >1.5
    • PTT >
    • total within normal institutional limits
    • (SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
    • creatinine within normal institutional limits OR
    • ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
  • (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification21. To be eligible for this trial, patients should be class 2B or better.
  • Review by multidisciplinary treatment conference consisting of mesothelioma surgeons, radiologists, pathologists, medical oncologists, and palliative care physicians. Date of review will be documented in on the patient's elgibility checklist
  • Prior or concurrent enrollment to UChicago's Mesothelioma Biobank (IRB15-0443).
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria

  • Patients with biphasic or sarcomatoid pleural mesothelioma.
  • Patients with disease or disease which extends to the abdominal cavity or subdiaphragm as identified on post-induction therapy cross sectional imaging (CT, MRI, or PET).
  • Patients who demonstrate disease progression during or following induction therapy.
  • \< 50% and/or postoperative predicted DLCO \< 50%.
  • Patients who are receiving any other agents.
  • Patients with uncontrolled intercurrent illness.
  • Prior active 2 years prior to registration except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast, or papillary thyroid.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    All Study Participants

    This study arm will include all study participants receiving a partial pleurectomy (Surgery) for unresectable pleural mesothelioma. Participants in this study arm will all receive the same study procedures.

    Procedure: Partial Pleurectomy

Interventions

  • ProcedurePartial Pleurectomy

    A partial pleurectomy is a surgical procedure where part of the pleura, the lining of the lung cavity, is removed. This may be done to remove tumors, excess tissue, or to treat lung complications.

07

What researchers measure

Primary outcomes

  1. Disease-related Symptom Burden 3 Months After Partial Pleurectomy (Surgery)

    The primary objective is to assess the post-operative disease-related symptom burden in participants undergoing partial pleurectomy and decortication for borderline or unresectable pleural mesothelioma, as measured by the mesothelioma-specific Lung Cancer Symptom Scale Average Symptom Burden Index (LCSS-meso ASBI) at 3 months post-surgery.

    Time frame: 3 months after surgery

Secondary outcomes

  1. Quality of Life of Study Participants Who Have Undergone Partial Pleurectomy (Surgery)

    To longitudinally evaluate quality of life in patients who have undergone partial pleurectomy and decortication as assessed by quality of life questionnaires and patient reported outcomes.

    Time frame: 2 years

  2. Rate of Complications after Partial Pleurectomy (Surgery)

    To estimate the rate of complications following partial pleurectomy and decortication as assessed by treating investigator and clinical notes.

    Time frame: 2 years

  3. Time to Resumption of Systemic Therapy

    To determine time to resumption of systemic therapy following partial pleurectomy and decortication as assessed by treating investigator and clinical notes.

    Time frame: 2 years

  4. Overall Survival of Study Participants Who Have Undergone Partial Pleurectomy (Surgery)

    To estimate overall survival in participants who have undergone partial pleurectomy and decortication as assessed by treating investigator and clinical notes.

    Time frame: 2 years

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 17, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07126509
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Dec 2, 2025
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Cancer Trials Intake
Contact
cancerclinicaltrials@bsd.uchicago.edu
1-855-702-8222
Darren Bryan, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion